

Docket No. ROC0026DIV1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Theresa Callaghan et al.

Serial No. : 10/721,537

Art Unit: 1654

Filed : November 25, 2003

Examiner:

For : METHOD FOR THE TOPICAL TREATMENT AND PREVENTION OF
INFLAMMATORY DISORDERS AND RELATED CONDITIONS
USING EXTRACTS OF FEVERFEW (TANACETUM PARTHENIUM)

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

March 18, 2004
(Date of Deposit)

Andrea L. Colby
(Name of applicant, assignee, or Registered Representative)

Andrea L. Colby
(Signature)

March 18, 2004
(Date of Signature)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☒ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the



Optional stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i)).

☐ There are no listed references which are not in the English language.


☒ The relevance of those listed references which are not in the English language is as follows: English language abstracts are provided for WO 94/06800 and WO 97/02807.

☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ROC26DIV1/ALC. This form is submitted in triplicate.

Respectfully submitted,


Andrea L. Colby
Reg. No. 30,194
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2792

DATED: *March 18, 2004*



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3

Application Number	10/721,537
Filing Date	November 25, 2003
First Named Inventor	Theresa Callaghan
Group Art Unit	1654
Examiner Name	
Attorney Docket Number	ROC0026 DIV1

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
		3,755,560	A	Dickert et al.	08/28/1973	
		4,254,105	A	Fukuda	03/03/1981	
		4,421,769	A	Dixon et al.	12/20/1983	
		4,758,433	A	Johnson et al.	07/19/1988	
		4,960,764	A	Figuerola, Jr. et al.	10/02/1990	
		5,260,065	A	Mathur et al.	11/09/1993	
		6,103,218	A	Brucker et al.	08/15/2000	
		6,153,208	A	McAtee et al.	11/28/2000	
		6,130,254	A	Fisher et al.	10/10/2000	
		6,224,875	B1	Bombardelli et al.	05/01/2001	
		6,410,062	B1	Callaghan et al. (Docket ROC0021)	06/25/2002	
		6,479,080	B2	Bombardelli et al.	11/12/2002	
		6,620,419	B1	Lintner	09/16/2003	
		2001/0021400	A1	Bombardelli et al.	09/13/2001	
		2002/0182166	A1	Martin et al. (Docket J&J2097)	12-05-2002	
		2003/0003170	A1	Callaghan et al.	01/02/2003	
		2003/0077343	A1	Martin et al. (Docket J&J2138)	04/24/2003	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵				
		EPO	0 273 202	B1	Van Scott, Eugene J., Dr.	06/21/1995		
		EPO	0 427 411	B1	Richardson Vicks, Inc.	05/15/1991		
		WO	94/06800	A1	Madeca	03/31/1994	English Abstract	N
		WO	96/31194	A2	Johnson & Johnson Consumer Co.	10/10/1996		
		WO	97/02807	A1	C 3 D	01/30/1997	English Abstract	N
		WO	00/74695	A2	Indena S.P.A.	12/14/2000		
		WO	00/74699	A1	Johnson & Johnson Consumer FR	12/14/2000		
		WO	02/074280	A1	Johnson & Johnson Consumer Co.	09/26/2002		

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3

Application Number	10/721,537
Filing Date	November 25, 2003
First Named Inventor	Theresa Callaghan
Group Art Unit	1654
Examiner Name	
Attorney Docket Number	ROC0026 DIV1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		JOHNSON, TIMOTHY, CRC Ethnobotany Desk Reference, CRC Press, NY, 1999, pp.198-199,516-517,823-824.	
		International Plant Names Index published on the Internet, http://www.ipni.org .	
		CONNOR, MICHAEL, WHEELER, LARRY, Depletion of Cutaneous Glutathione by Ultraviolet Radiation, Photochemistry and Photobiology, 1987, Vol. 46, No. 2, pp. 239-245.	
		FISHER, GARY J., VOORHEES, JOHN J., Molecular Mechanisms of Photoaging and its Preventions by Retinoic Acid: Ultraviolet Irradiation Induces MAP Kinase Signal Transduction Cascades that Induce AP-1-Regulated Matrix Metalloproteinases that Degrade Human Skin In Vivo, The Society for Investigative Dermatology, Inc. 1998pp. 61-68.	
		FISHER, GARY J., SUBHASH C. DATTA, HARVINDER S. TALWAR, ZENG-QUAN WANG, JAMES VARANI, SEWON KANG AND VOORHEES, JOHN J., Nature, 1996, Vol 379, pp.335-339.	
		HANADA, KATSUMI, SAWAMURA, DAISUKE, TAMAI, KATSUTO, HASHIMOTO, ISAO, KOBAYASHI, SHIZUKO, Photoprotective Effect of Esterified Glutathione Against Ultraviolet B-Induced Sunburn Cell Formation in the Hairless Mice, The Society for Investigative Dermatology, Inc. 1997, pp.727-730.	
		HAUSEN, B.M. AND SCHULZ, K.H., Chrysanthemum Allergy, Arch. Derm. Res. 1976, Vol. 255, pp.111-121	
		MENAGE, H.DUP., ROSS, J.S., NORRIS, P.G. HAWK, J.L.M., WHITE I.R., Contact and Photocontact Sensitization in Chronic Actinic Dermatitis: Sesquiterpene Lactone Mix is an Important Allergen, British Journal of Dermatology, 1995:132:543-547.-	
		MEISTER, ALTON, Glutathione, Ascorbate, and Cellular Protection, Cancer Research Suppl, 54,1994,pp. 1969s-1975s.	
		MEZEI, MICHAEL, Liposomes as a Skin Drug Delivery System, Elsevier Science Publishers, NY,1985,pp.345-358.	
		MEZEI, MICHAEL, GULASEKHARAM, VIJEYALAKSHMI, Liposomes-A Selective Drug Delivery System for the Topical Route of Administration: Gel Dosage Form, J. Pharm. Pharmacol, 1982,34:473-474.	
		ORION, E., PAULSEN, E., ANDERSEN, K.E., MENNE T., Comparison of Simultaneous Patch Testing with Parthenolide and Sesquiterpene Lactone Mix, Contact Dermatitis 1998,38:207-208.	
		SPETTOLI, ELISA, SILVANI, SIMONETTA, LUCENTE, PASQUALE, GUERRA, LILIANA, VINCENZI, COLOMBINA, Contact Dermatitis Caused by Sesquiterpene Lactones, American Journal of Contact Dermatitis, Vol.9, No. 1, 1998:pp.49-50.	
		SCHULZ,K.H., HAUSEN, B.M., WALLHOFFER, SCHMIDT-LOFFLER, P., Chrysanthemum-Allergic, Arch. Derm. Forsch, 1975,251:pp.235-244.	
		STEENVOORDEN, DAVID, HASSELBAINK, DANNY, BEIJERSBERGEN VAN HENEGOUWEN, GERARD M.J., Protection Against UV-Induced Reactive Intermediates In Human Cells And Mouse Skin By Glutathione Precursors: A Comparison Of N-Acetylcystein And Glutathione Ethylester, Photochemistry and Photobiology, 1998,67(6):pp.651-656.	
		TYRRELL, R.M., PIDOUX, M., Correlation Between Endogenous Glutathione Content and Sensitivity of Cultured Human Skin Cells to Radiation at Defined Wavelengths in the Solar Ultraviolet Range, Photochemistry and Photobiology, 1998, Vol. 47, No. 3, ppd. 405-412.	
		VAN DEN BROEKE, LEON T., BEIJERSBERGEN VAN HENEGOUWEN, GERARD, M. J., Topically applied N-acetylcysteine as a protector against UVB-induced systemic immunosuppression, Journal of Photochemistry and Photobiology, B: Biology 27, 1995:pp. 61-65.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

3 of 3

Application Number	10/721,537
Filing Date	November 25, 2003
First Named Inventor	Theresa Callaghan
Group Art Unit	1654
Examiner Name	
Attorney Docket Number	ROC0026 DIV1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		SAGARIN, EDWARD AND BALSAM, M.S., Cosmetics Science and Technology, Second Edition, Vol. 1, (1972) pp.32-43	
		WENNINGER, JOHN A., MCEWEN, G.N. JR., International Cosmetic Ingredient Dictionary and Handbook, Seventh Edition (1997) Vol. 2, The Cosmetic, Toiletry, and Fragrance Association, Washington, DC, pp. 1626, 1650-1667, 1654-1661, 1693-1697, 1673-1686.	
		BARSBY, R.W.J. SALAN, UMIT, NIGHT, D.W., HOULT, J.R.S., Feverfew and Vascular Smooth Muscle: Extracts from Fresh and Dried Plants Show Opposing Pharmacological Profiles, Dependent upon Sesquiterpene Lactone Content, Planta Med. 59(1993) pp.20-25.	
		LAMMINPAA, ANNE, ESTLANDER TUULA, JOLANKI, RHTTA, KANERVA, LASSE, Occupational allergic contact dermatitis caused by decorative plants, Contact Dermatitis, 1996, 34:pp.330-335.	
		XP002147441, Biosis: Biosciences Information Service, Barasby R.W.J. et al.:Philadelphia, PA 1993.	
		Derwent English abstract of HU 210294B (1995)	
		TITHERADGE, MICHAELA., The Enzymatic Measurement of Nitrate and Nitrite, Methods in Molecular Biology, Vol. 100, publicly available prior to March 1, 2002, pp. 83-91.	
		DETMAR, MICHAEL, The Role of VEGF and thrombospondins in skin angiogenesis, Journal of Dermatological Science, 24 Suppl. 1 (2000)S78-S84.	
		KOLLIAS, N., BAQER, A. SADIQ, i. SAYRE, R.M., In vitro AND in vivo ULTRAVIOLET-INDUCED ALTERATIONS OF OXY-AND DEOXYHEMOGLOBIN, Photochemistry and Photobiology vol. 56, no. 2, (1991) pp. 223-227	
		GUY, R.H. AND MAIBACH, H.I., Rapid Radial Transport of Methyl Nicotinate in the Dermis, Arch Dermatol Res (1982)273:91-95	
		YANCOPOULOS, GEORGE D., DAVIS, SAMUEL, GALE, NICHOLAS W., RUDGE, JOHN S., WIEGAND STANLEY J., HOLASH, JOCELYN, Vascular-specific growth factors and blood vessel formation, Nature, vol. 407, (2000)pp. 242-248.	
		BIKFALVI, ANDREAS, KLEIN, SHARON, PINTUCCI, GIUSEPPE, RIFKIN, DANIEL B., Biological Roles of Fibroblast Growth Factor-2*, Endocrine Reviews, vol. 18, no. 1, pp.26-45.	
		GERBER, HANS-PETER, MCMURTREY, AMY, KOWALSKI, JOE, YAN, MINHONG, KEYT, BRUCE A, DIXIT, VISHVA, FERARA, NAPOLEONE, Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3'-Kinase/Akt Signal Transduction Pathway, The Journal of Biological Chemistry, (1998), vol. 273, no. 46, pp.30336-30343.	
		McCutcheon's Emulsifiers & Detergents, 1986 (North Edition), McPublishing Co., Glen Rock, NJ, pp317-324.	
		BAREL, A.O., COURAGE, W. CLARYS, P., Suction Method for Measurement of Skin Mechanical Properties: The Cutometer®, Handbook of Non-Invasive Methods and the Skin, eds. J. Serup & G. Jemec, Chapter 14.3(1995) pp. 335-340.	
		Abstract, Acta Derm Venereol 1983;63(4):308-14, Contact allergy to parthenolide in Tanacetum parthenium (L.) Schulz-Bip. (feverfew, Asteraceae) and cross-reactions to related sesquiterpene lactone containing Compositae species.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 2023